Apoptotic cell death and rupture of abdominal aortic aneurysm

Medical Hypotheses

Volumn 74, Issue 5, 2010, Pages 908-910

  Kovacevic, M ^a   Jonjic, N ^a   Stalekar, H ^a   Zaputovic, L ^a   Stifter, S ^a   Vitezic, D ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL AORTA ANEURYSM; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CYTOKINE PRODUCTION; DRUG MEGADOSE; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; NICK END LABELING; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; SMOOTH MUSCLE FIBER; TISSUE DEGENERATION;

AORTIC ANEURYSM, ABDOMINAL; APOPTOSIS; HUMANS; MODELS, BIOLOGICAL; MYOCYTES, SMOOTH MUSCLE;

ANIMALIA;

EID: 77950955969     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.10.021     Document Type: Article

References (26)

1. Singh K., Bonaa K.H., Jacobsen B.K., Bjork L., Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the tromso study. Am J Epidemiol 2001, 154:236-244.
2. Simoni G., Pastorino C., Perrone R., Ardia A., Gianrossi R., Decian F., et al. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg 1995, 10:207-210.
3. Liu J., Sukhova G.K., Yang J.T., Sun J., Ma L., Ren A., et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 2006, 184:302-311.
4. Moran C.S., McCann M., Karan M., Norman P., Ketheesan N., Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005, 111:3119-3125.
5. Shi G.P., Sukhova G.K., Grubb A., Ducharme A., Rhode L.H., Lee R.T., et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999, 104:1191-1197.
6. Pan J.H., Lindholt J.S., Sukhova G.K., Baugh J.A., Henneberg E.W., Bucala R., et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. J Vasc Surg 2003, 37:628-635.
7. Walton L.J., Franklin I.J., Bayston T., Brown L.C., Greenhalgh R.M., Taylor G.W., et al. Inhibition of prostaglandin (PG) E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999, 100:48-54.
8. Meijer A., van Der Vliet J.A., Roholl P.J., Gielis-Proper S.K., de Vries A., Ossewaarde J.M. Chlamydia pneumoniae in abdominal aortic aneurysms: abundance of membrane components in the absence of heat shock protein 60 and DNA. Arterioscler Thromb Vasc Biol 1999, 19:2680-2686.
9. Porqueddu M., Spirito R., Parolari A., Zanobini M., Pompilio G., Polvani G., et al. Lack of association between serum immunoreactivity and Chlamydia pneumoniae detection in the human aortic wall. Circulation 2002, 106:2647-2648.
10. Sangiorgi G., D'Averio R., Mauriello A., Bondio M., Pontillo M., Castelvecchio S., et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 2001, 104:I288-I295.
11. Eugster T., Huber A., Obeid T., Schwegler I., Gurke L., Stierli P. Aminoterminal propeptide of type III procollagen and matrix metalloproteinases-2 and -9 failed to serve as serum markers for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2005, 29:378-382.
12. Lindholt J.S., Vammen S., Fasting H., Henneberg E.W., Heickendorff L. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms: a preliminary study. Eur J Vasc Endovasc Surg 2000, 20:281-285.
13. Kalyanasundaram A., Elmore J.R., Manazer J.R., Golden A., Franklin D.P., Galt S.W., et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006, 43:117-124.
14. Buckley C., Shames M.L., Ennis T.L., Vanvickle-Chavez S.J., Mao D., Goeddel L.A., et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005, 241:92-101. Steinmetz ejection factor (EF).
15. Manning M.W., Cassis L.A., Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003, 23:483-488.
16. Curci J.A., Petrinec D., Liao S., Golub L.M., Thompson R.W. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998, 28:1082-1093.
17. Liao S., Miralles M., Kelley B.J., Curci J.A., Borhani M., Thompson R.W. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001, 33:1057-1064.
18. Miralles M., Wester W., Sicard G.A., Thompson R., Reilly J.M. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 1999, 29:884-892.
19. King V.L., Trivedi D., Gitlin J.M., Loftin C.D. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006, 26:1137-1143.
20. Wilson W.R., Evans J., Bell P.R., Thompson M.M. 3hydroxy3methylglutaryl (HMG)-coenzymeA (CoA) reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005, 30:259-262.
21. Bjorkerud S., Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996, 149:367-380.
22. Isner J.M., Kearney M., Bortman S., Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation 1995, 91:2703-2711.
23. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119:493-501.
24. Schouten O., van Laanen J.H., Boersma E., Vidakovic R., Feringa H.H., Dunkelgrun M., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006, 32:21-26.
25. Vammen S., Lindholt J.S., Ostergaard L., Fasting H., Henneberg E.W. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Brit J Surg 2001, 88:1066-1072.
26. Franklin I.J., Walton L.J., Brown L., Greenhalgh R.N., Powell J.T. Vascular surgical society of Great Britain and Ireland: non-steroidal anti-inflammatory drugs to treat abdominal aortic aneurysm. Brit J Surg 1999, 86:707.